BRAINSWAY LTD. FORM 6-K FILING

This Form 6-K report details BrainsWay Ltd.'s financial performance and operational updates for the six-month period ending June 30, 2026. The company, a leader in non-invasive neurostimulation treatments for mental health disorders using its Deep TMS™ platform, reported revenues of $32.6 million for the period, a significant increase from $24.2 million in the same period of 2025. Net profit for the six months was $5.0 million, up from $3.1 million in the prior year. The company's balance sheet shows total assets of $122.0 million as of June 30, 2026, with total equity at $79.2 million. Key developments include FDA clearances for expanded indications, such as adolescent MDD treatment and an accelerated treatment protocol. The company also made strategic investments in other mental health service providers. The report also addresses potential impacts of geopolitical events and trade policies on its operations.